• Shiprocket

  Participated · Equity · Aug 2026

  Shiprocket operates as a horizontal e-commerce enablement platform serving merchants and large retailers, with operations split into Core Business and Emerging Business segments. Its Core Business includes domestic shipping and shipping applications, while Emerging Businesses comprise cargo and fulfillment, cross-border shipping, advertising and marketing solutions, capital solutions, and hyperlocal deliveries. According to a Redseer Report cited by the company, Shiprocket was the largest new-age, end-to-end horizontal e-commerce enablement platform in India by revenue from operations for fiscal 2026. The company is pursuing growth through both organic expansion of its shipping and fulfillment offerings and by building out adjacent services such as advertising, capital solutions, and cross-border logistics. As part of its IPO, Shiprocket has signaled plans to invest in marketing and technology infrastructure, repay or prepay certain borrowings, and consider potential acquisitions using proceeds from the fresh issue. Current public disclosures around revenue, users, or founding year were not provided in the article.

• Molbio Diagnostics

  Participated · Equity · Aug 2026

  Incorporated in 2000 and based in Goa, Molbio Diagnostics develops and manufactures the Truenat point-of-care PCR platform and test kits for molecular diagnosis across more than 30 diseases including tuberculosis, COVID, HIV, HPV and hepatitis B and C. Its battery-operated Truenat platform is patented in over 100 countries and is designed for deployment in resource-limited settings to enable decentralized diagnosis within an hour. The company operates six manufacturing facilities in India (two in Goa, two in Bengaluru, and one each in Visakhapatnam and Pune) with an installed capacity of 5,400 devices per annum and 3.9 crore Truenat test kits annually as of March 31, 2026. Financially, Molbio reported revenue from operations of ₹1,445 crore and profit of ₹164 crore for fiscal 2026. The company intends to expand R&D and manufacturing capacity using proceeds from its IPO, including funds earmarked for a Centre of Excellence, additional infrastructure and new plant and machinery. Its shares are proposed to be listed on the BSE and NSE on August 17, 2026.

• Capillary Technologies

  Participated · Equity · Nov 2025

  Capillary Technologies India is a software product company offering artificial-intelligence-driven, cloud-native SaaS applications that help enterprise customers deepen consumer and channel-partner loyalty. Its platform is deployed globally, targeting large enterprises that want to enhance engagement and retention. For the six months ended September 2025, the company recorded consolidated revenue of ₹359.21 crore, following FY 25 revenue of ₹598.25 crore. To accelerate growth, the company is moving toward a public listing on the BSE and NSE. A portion of the IPO proceeds will come from a fresh issue of shares, providing new capital to the business. Capillary’s upcoming listing is being managed by JM Financial, IIFL Capital Services and Nomura Financial Advisory & Securities (India), with MUFG Intime India acting as registrar. The firm’s strategy centers on expanding its AI-driven loyalty product suite and scaling its global enterprise footprint.

• Groww

  Participated · Equity · Nov 2025

  Founded in 2016, Groww began as a direct-to-consumer mutual fund distributor and has evolved into a full-stack wealth management platform offering stockbroking, digital lending, and allied financial services. It now holds the position of India’s largest stockbroker with 13 million active traders as of February, outpacing rivals Zerodha and Angel One. The company recently deepened its advisory capabilities by acquiring PayU-backed fintech Fisdom for roughly $150 million. Financially, Groww’s FY25 revenue rose 31 % year-over-year to Rs 4,056 crore while net profit more than tripled to Rs 1,819 crore, a sharp turnaround from the prior year’s one-time tax-driven net loss. Its valuation has more than doubled since 2021, reflecting strong investor confidence. In May, Groww confidentially filed draft papers with SEBI for an IPO targeting $700 million–$1 billion, underscoring its near-term expansion ambitions. Existing backers include Peak XV Partners, Tiger Global, Ribbit Capital, Iconiq Capital, and Singapore’s sovereign wealth fund GIC.

• Rubicon Research

  Participated · Equity · Oct 2025

  Rubicon Research focuses on the research, development, and manufacturing of specialty pharmaceutical formulations targeted primarily at regulated markets, with a particular emphasis on the U.S. market. The company operates two FDA-inspected R&D centers and two manufacturing plants that support its product pipeline. Its strategy includes both organic growth through continued product development and inorganic growth via acquisitions. Ahead of its IPO, the company highlighted plans to direct ₹310 crore of fresh-issue proceeds toward debt repayment, thereby strengthening its balance sheet. Additional funds will be earmarked for future acquisitions to broaden its portfolio and geographic reach. The total IPO is structured at ₹1,377.5 crore, combining a ₹500 crore fresh issue with an ₹877.5 crore offer for sale by promoter General Atlantic Singapore. Following the IPO, General Atlantic’s stake is expected to fall by roughly 35%, diversifying Rubicon’s shareholder base. The successful anchor book signals strong institutional confidence in the company’s growth prospects.

No current team members are available.